Adishesh M, Fyson A, DeCruze S B, Kirwan J, Werner H M J, Hapangama D K
Liverpool Women's Hospital NHS Foundation Trust, Crown Street, Liverpool L8 7SS, UK.
Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool Women's Hospital, Crown Street, Liverpool L8 7SS, UK.
Br J Cancer. 2017 Aug 8;117(4):485-493. doi: 10.1038/bjc.2017.194. Epub 2017 Jun 29.
Endometrial cancer is the most common gynaecological cancer and its incidence is predicted to escalate by 50-100% in 2025 with a parallel increase in associated mortality. Variations in the collection, processing and storage of biospecimens can affect the generalisability of the scientific data. We aimed to harmonise the collection of biospecimens, clinical data relevant to endometrial cancer and to develop standard operative procedures for the collection, processing and storage of endometrial cancer biospecimens.
We designed research tools, which were evaluated and revised through three consensus rounds - to obtain local/regional, national and European consensus. Modified final tools were disseminated to a panel (n=40) representing all stakeholders in endometrial cancer research for consensus generation.
The final consensus demonstrated unanimous agreement with the minimal surgical and patient data collection tools. A high level of agreement was also observed for the other remaining standard tools.
We here present the final versions of the tools, which are freely available and easily accessible to all endometrial cancer researchers. We believe that these tools will facilitate rapid progress in endometrial cancer research, both in future collaborations and in large-scale multicentre studies.
子宫内膜癌是最常见的妇科癌症,预计到2025年其发病率将上升50%至100%,相关死亡率也会随之增加。生物样本的采集、处理和存储方式的差异会影响科学数据的普遍性。我们旨在统一子宫内膜癌生物样本的采集、与子宫内膜癌相关的临床数据,并制定子宫内膜癌生物样本采集、处理和存储的标准操作程序。
我们设计了研究工具,通过三轮共识会议对其进行评估和修订,以达成地方/区域、国家和欧洲层面的共识。修改后的最终工具被分发给一个由40名代表子宫内膜癌研究所有利益相关者的小组,以达成共识。
最终共识表明,对于最小限度的手术和患者数据收集工具,大家达成了一致意见。对于其他剩余的标准工具,也观察到了高度的一致性。
我们在此展示这些工具的最终版本,所有子宫内膜癌研究人员均可免费获取且易于使用。我们相信,这些工具将促进子宫内膜癌研究在未来合作以及大规模多中心研究中的快速进展。